Spots Global Cancer Trial Database for Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
Official Title: Neoadjuvant Nivolumab for Operable Esophageal Squamous Cell Carcinoma
Study ID: NCT03987815
Conditions
Interventions
Study Description
Brief Summary: This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jong-Mu Sun, Seoul, , Korea, Republic of
Contact Details
Name: Jong-Mu Sun
Affiliation: Samsung Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
